Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cilengitide Merck.

Jeffrey W Smith¹

¹Burnham Institute, 10901 N Torrey Pines Road, La Jolla, CA 92037-1005, USA. jsmith@burnham.org

Current Opinion in Investigational Drugs (London, England : 2000)

|August 7, 2003

Summary

This summary is machine-generated.

Cilengitide, an integrin antagonist, is being investigated for various cancers. Clinical trials are evaluating its efficacy in non-small-cell lung cancer, pancreatic cancer, and glioblastoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Vascular Proteome Responses Precede Organ Dysfunction in a Murine Model of Staphylococcus aureus Bacteremia.

mSystems·2022

Same author

Coagulation factor protein abundance in the pre-septic state predicts coagulopathic activities that arise during late-stage murine sepsis.

EBioMedicine·2022

Same author

Quantitative profiling of protease specificity.

PLoS computational biology·2021

Same author

Proteomic atlas of organ vasculopathies triggered by Staphylococcus aureus sepsis.

Nature communications·2019

Same author

Plasma Proteome Signature of Sepsis: a Functionally Connected Protein Network.

Proteomics·2019

Same author

Correction for Fogal et al., "Mitochondrial p32 Protein Is a Critical Regulator of Tumor Metabolism via Maintenance of Oxidative Phosphorylation".

Molecular and cellular biology·2017

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Oncology
Pharmacology

Background:

Merck KGaA is developing cilengitide, a novel integrin antagonist.
Cilengitide exhibits anti-angiogenic properties, targeting tumor blood vessel formation.

Purpose of the Study:

To evaluate cilengitide's potential in treating various cancer types.
To assess cilengitide's efficacy as a monotherapy and in combination with other agents.

Main Methods:

Phase II clinical trials initiated in 1999 for non-small-cell lung cancer (monotherapy) and pancreatic cancer (combination with gemcitabine).
Phase I and Phase I/II trials in glioblastoma were underway by February 2002.

Main Results:

Clinical trials were ongoing as of February 2002, indicating continued investigation.

Related Experiment Videos

Specific efficacy results are not detailed in the provided abstract.

Conclusions:

Cilengitide is under active clinical investigation for multiple cancer indications.
The development of cilengitide represents a targeted approach to cancer therapy through integrin antagonism.